User:Mr. Ibrahem/Gefitinib

Gefitinib, sold under the brand name Iressa, is a medication used to treat non-small cell lung cancer (NSCLC). Specifically it is used in cases which have certain mutations of the epidermal growth factor receptor. It is taken by mouth.

Common side effects include rash, diarrhea, nausea, fever, mouth inflammation, eye problems, liver problems, and kidney problems. Other side effects may include interstitial lung disease and infertility. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor and EGFR inhibitor.

Gefitinib was approved for medical use in the United States in 2003 and Europe in 2009. It is on the World Health Organization's List of Essential Medicines as an alternative to erlotinib. It is available as a generic medication. In the United Kingdom a month costs the NHS about £2,200 as of 2021. This amount in the United States costs about 8,100 USD.